To access the live call by phone, dial 913-312-1463; the conference ID
is 3243361. The call also may be accessed through the Investors section
of the Company's website, www.immunogen.com.
Following the live webcast, a replay of the call will be available at
the same location through
ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary antibody-drug conjugate ("ADC") technology. ImmunoGen's lead product candidate, mirvetuximab soravtansine, is being advanced to registration-enabling testing for FRα-positive platinum-resistant ovarian cancer, and is also in Phase 1b/2 testing in combination regimens for earlier-stage disease. ImmunoGen's ADC technology is used in Roche's marketed product, Kadcyla®, in three other clinical-stage ImmunoGen product candidates, and in programs in development by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda.
Kadcyla® is a registered trademark of Genentech, a member of the Roche Group.
News Provided by Acquire Media